Summary
This study presents results of investigations of lumbar and ventricular cerebrospinal fluid (CSF) biochemical markers (Beta-glucuronidase (B-gluc), Beta-2-microglobulin (B2-m), and carcinoembrionic antigen (CEA)) in 28 patients with five different tumor types with leptomeningeal metastasis diagnosed by CSF cytology and/or autopsy. All received methotrexate and radiotherapy at some stage. Decadron or other symptomatic treatments were not used.
Measurements of the concentrations of B-gluc, B2-m and CEA were evaluated with the aim of correlating the results of these measurements to site of disease, of monitoring response and early relapse of leptomeningeal disease, and of establishing the duration of survival. than those obtained from lumbar CSR
The markers did not correlate with site of disease or CSF cytology. A clear relationship was found between pretreatment lumbar CSF B2-m and CEA levels, response to therapy and survival. The markers are also useful for monitoring response. The findings of this study indicate that B2-m and CEA levels have a prognostic value with regard to response to therapy and time of survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
1.van Zanten AP, Twijnstra A, van Benthem V, Hart AAM, Ongerboer de Visser BW: Cerebrospinal fluid B-glucuronidase activities in patients with central nervous system metastases. Clin Chim Acta 147: 127–134, 1985
Twijnstra A, Nooyen WJ, van Zanten AP, Hart AAM, Ongerboer de Visser BW: Cerebrospinal fluid beta-2-microglobulin: a study in controls and patients with matastatic and nonmetastatic neurological diseases. Eur J Cancer and Clin Oncol 22:387–391, 1986
Twijnstra A, Nooyen WJ, van Zanten AP, Ongerboer de Visser BW, Hart AAM: Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and non-metastatic neurological diseases. Arch Neurol 43:269–272, 1986
van Zanten AP, Twijnstra A, Hart AAM, Ongerboer de Visser BW. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta 161:259–268, 1986
Koch TR Lichtenfeld KM, Wiernik PH: Detection of central nervous system metastases with cerebrospinal fluid B2-microglobulin. Cancer 52:101–104, 1986
Yap BS, Yap HY, Fritsche HA, Blumenschein G, Bodey GP: Cerebrospinal fluid carcinoembryonic antigen in breast cancer patients with meningeal carcinomatosis. JAMA 244:1601–1603, 1980
Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 8:597–604, 1980
Mavligit GM, Stuckey SE, Cabanillas FF, Keating MJ, Tourtelotte WW Schols SC, Freirich EJ: Diagnosis of leukemia or lymphoma in the central nervous system by beta-2-microglobulin determination. N Engl J Med 303:718–722, 1980
Twijnstra A, van Zanten AP, Hart AAM, Ongerboer de Visser BW: Serial lumbar and ventricle cerebrospinal fluid lactate hydrogenase activities in patients with leptomeningeal metastases from solid and hematological tumors. J Neurol, Neurosurg and Psychiat 50:313–320, 1987
Glass JP, Melamed M, Chernik NL, Posner JB: Malignant cells in cerebrospinal fluid (CSF); the meaning of a positive CSF cytology. Neurology 29:1369–1375, 1979
Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AAM, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from brast carcinoma. Neurology (Cleveland) 33:1565–1572, 1983
Shapiro WR, Young DF, Metha BM: Methotrexate: Distribution in cerebrospinal fluid after intravenous ventricular and lumbar injections. N Engl J Med 293:161–166, 1975
Persyn JP, Korsten CB: The development of a radioimmunoassay for carcinoembrionic antigen with some application. J Clin Chem Clin Biochem 14:377–387, 1976
Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 591–596, 1965
Cox DR: Regression models and life tables. J Roy Statist Soc 8 34:187–202, 1972
Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB: Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Sci 11: no. 3, 1981
Murray JJ, Greco FA, Wolff SN, Hainsworth JD: Neoplastic meningitis marked variations of cerebrospinal fluid after intravenous ventricular in the absence of extradural block. Americ J Med 75:289–294, 1983
Sculier JP: Treatment of meningeal carcinomatosis. Cancer Treat Reviews 12:95–104, 1985
Kaplan E, Meyer P: Nonparametric estimation from incomplete observation. J Amer Stat Ass 53:457–481, 1958
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Twijnstra, A., Ongerboer de Visser, B.W., van Zanten, A.P. et al. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neuro-Oncol 7, 57–63 (1989). https://doi.org/10.1007/BF00149379
Issue Date:
DOI: https://doi.org/10.1007/BF00149379